Kringle Pharma Commences a Phase I/II Clinical Trial in Sweden on ChronSeal, a Recombinant Human HGF-Based Therapy for the Treatment of Skin Ulcers.

Kringle Pharma Commences a Phase I/II Clinical Trial in Sweden on ChronSeal^®, a Recombinant Human HGF-Based Therapy for the Treatment of Skin Ulcers.